Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.39 |
| ▸ | LPL | P06858 | 3/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20599801 | 1.00 | SLC6A4 (0.44) | SLC6A4LIPGLPLDGAT1FFAR1 | |
| SCHEMBL20600222 | 0.86 | SLC6A4 (0.60) | SLC6A4CACNA2D1HRH3 | |
| SCHEMBL20622437 | 0.86 | SLC6A4 (0.60) | SLC6A4CACNA2D1HRH3 | |
| SCHEMBL20600224 | 0.86 | SLC6A4 (0.60) | SLC6A4CACNA2D1HRH3 | |
| SCHEMBL20600192 | 0.82 | SLC6A9 (0.43) | SLC6A4SLC6A9HRH3 | |
| SCHEMBL20600172 | 0.82 | LPL (0.41) | LIPGLPLCACNA2D1 | |
| SCHEMBL20600194 | 0.82 | SLC6A4 (0.44) | SLC6A4CACNA2D1 | |
| SCHEMBL16382831 | 0.81 | LIPG (0.44) | SLC6A4LIPGLPLDGAT1 | |
| SCHEMBL20599772 | 0.78 | SLC6A9 (0.42) | SLC6A9 | |
| SCHEMBL251859 | 0.76 | LIPG (0.44) | LIPGLPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3645528-A1 | COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-05-06 | — | — | EP | disclosed |
| US-20200123115-A1 | COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-04-23 | — | — | US | disclosed |
| WO-2019002173-A1 | COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123115-A1 | COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | TRPV1, CACNG2, CACNA1B | SLC6A4 1226/4885LIPG 3200/4885LPL 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.